SIENNA BIOPHARMACEUTICALS, INC.
SIENNA BIOPHARMACEUTICALS, INC. (SNNA): 1 pipeline candidate · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.4 months
D/E 0.88 · 0% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for SIENNA BIOPHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$11.5M
Quarterly Burn
$17.8M
Runway
2.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| sna-120 | Phase 3 |
Frequently asked questions
How many drug candidates are in SIENNA BIOPHARMACEUTICALS, INC.'s pipeline?
SIENNA BIOPHARMACEUTICALS, INC. (SNNA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is SIENNA BIOPHARMACEUTICALS, INC.'s lead drug candidate?
SIENNA BIOPHARMACEUTICALS, INC.'s most advanced tracked candidate is sna-120 (Phase 3) for psoriasis and the associated pruritus.
What is SIENNA BIOPHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SIENNA BIOPHARMACEUTICALS, INC. has approximately 2.4 months of cash runway.
Who is the CEO of SIENNA BIOPHARMACEUTICALS, INC.?
Todd Harris, Ph.D. is the chief executive officer of SIENNA BIOPHARMACEUTICALS, INC. (SNNA).
Get the full picture on SIENNA BIOPHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.